Eyenuk Secures European Union Certification for Autonomous AI-Powered Detection of Age-Related Macular Degeneration and Glaucoma

The approval allows Eyenuk’s AI eye screening system to aid millions of additional patients at risk for vision loss

The EyeArt AI system previously received both FDA clearance in the US and CE marking in the EU enabling its use for autonomous detection of diabetic retinopathy (DR), the leading cause of blindness among working-age adults globally. The new European Commission (EC) certification of the EyeArt AI system as a Class IIb medical device under the EU’s Medical Devices Regulation 2017/745 (“MDR”) allows Eyenuk customers in Europe to optionally detect AMD and glaucoma in addition to DR in a single exam using the same set of retinal images. The new certification also ensures continuous market access of the EyeArt AI system in the EU and comes at a time when the new regulation’s more stringent requirements and higher safety standards reportedly have many medical device companies considering exiting the EU market.

The EyeArt AI system greatly expands the availability of vision-saving eye screenings by making automated AI diagnosis and coordination of care possible in primary care medical practices without the need for a specialist’s review. The system is integrated with retinal imaging cameras and can be operated by clinical support staff to generate a detailed screening report in less than 30 seconds. In regions with limited access to ophthalmologists, its ability to detect multiple eye diseases with a single exam may help reduce the prevalence of vision-threatening eye disease.

“Achieving MDR certification is another major milestone for Eyenuk and a result of our early adaptation to the more stringent requirements of the new regulation,” said Kaushal Solanki, Chief Executive Officer and Founder of Eyenuk. “Moreover, this certification expanding our ability to market the EyeArt platform for two additional disease conditions in the EU reflects the flexibility of our AI-based platform and the depth of the clinical research conducted across the globe validating its effectiveness.”

Solanki continued, “DR, AMD, and glaucoma are all asymptomatic in their early stages. The sensitivity of the EyeArt AI algorithm, and its ability to be delivered without a specialist, makes it easier to catch the diseases early and to take preventative measures to protect the vision of these patients. We look forward to the opportunity to forge new partnerships with world-class hospitals and eyecare institutions in Europe to help preserve the eyesight of millions across the continent with these diseases.”

EC Certification Caps Year of Breakthroughs for Eyenuk

The EC Certification of the EyeArt AI system caps a year of significant clinical and business milestones for Eyenuk. The company’s accomplishments in 2022 included:

  • Securing $26 million in a Series A financing round, bringing the company’s total funding to over $43 million
  • Reaching the new milestone of 70,000 patients screened for DR globally, by far the most screenings by any autonomous AI system
  • Growing the number of locations using the EyeArt AI system to more than 200 in 18 countries and 14 U.S. states
  • Publication of a major peer-reviewed study finding that the EyeArt AI system is far more sensitive in identifying referable DR than dilated eye exams by ophthalmologists and retina specialists
  • Winning Juniper Research’s Future Digital Health award for the “Best Digital Diagnostics Solution”
  • Being named a finalist for the UCSF Digital Health Award
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy